4D Molecular Therapeutics, Inc. (FDMT)
15.22
+0.54
(+3.68%)
USD |
NASDAQ |
Sep 18, 16:00
15.08
-0.14
(-0.92%)
Pre-Market: 20:00
4D Molecular Therapeutics Enterprise Value : 518.24M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 518.24M |
| September 17, 2026 | 488.43M |
| September 16, 2026 | 437.63M |
| September 15, 2026 | 430.45M |
| September 14, 2026 | 437.63M |
| September 11, 2026 | 405.05M |
| September 10, 2026 | 422.72M |
| September 09, 2026 | 460.82M |
| September 08, 2026 | 485.67M |
| September 04, 2026 | 504.44M |
| September 03, 2026 | 489.53M |
| September 02, 2026 | 502.78M |
| September 01, 2026 | 470.21M |
| August 31, 2026 | 456.95M |
| August 28, 2026 | 487.87M |
| August 27, 2026 | 501.13M |
| August 26, 2026 | 537.01M |
| August 25, 2026 | 545.85M |
| August 24, 2026 | 527.63M |
| August 21, 2026 | 551.92M |
| August 20, 2026 | 566.83M |
| August 19, 2026 | 603.27M |
| August 18, 2026 | 490.63M |
| August 17, 2026 | 480.97M |
| August 14, 2026 | 350.94M |
| Date | Value |
|---|---|
| August 13, 2026 | 321.13M |
| August 12, 2026 | 333.27M |
| August 11, 2026 | 311.19M |
| August 10, 2026 | 292.97M |
| August 07, 2026 | 271.43M |
| August 06, 2026 | 260.39M |
| August 05, 2026 | 245.48M |
| August 04, 2026 | 244.38M |
| August 03, 2026 | 234.99M |
| July 31, 2026 | 239.96M |
| July 30, 2026 | 233.89M |
| July 29, 2026 | 208.49M |
| July 28, 2026 | 221.74M |
| July 27, 2026 | 251.01M |
| July 24, 2026 | 233.89M |
| July 23, 2026 | 251.01M |
| July 22, 2026 | 283.03M |
| July 21, 2026 | 305.94M |
| July 20, 2026 | 290.21M |
| July 17, 2026 | 284.69M |
| July 16, 2026 | 276.40M |
| July 15, 2026 | 322.78M |
| July 14, 2026 | 323.89M |
| July 13, 2026 | 301.80M |
| July 10, 2026 | 357.57M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Amgen, Inc. | 251.80B |
| AnaptysBio, Inc. | 1.593B |
| Precision BioSciences, Inc. | 116.86M |
| Design Therapeutics, Inc. | 561.25M |
| Inhibrx Biosciences, Inc. | 1.657B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -72.94M |
| Revenue (Quarterly) | 3.781M |
| Total Expenses (Quarterly) | 76.72M |
| EPS Diluted (Quarterly) | -1.038 |
| Gross Profit Margin (Quarterly) | 44.75% |
| Profit Margin (Quarterly) | -1.93K% |
| Earnings Yield | -17.90% |
| Normalized Earnings Yield | -17.90 |